Evidence map›Paper›PMID 42667390›Full record

ReviewDiabetologia2026

Metabolic and macrovascular outcomes following simultaneous pancreas-kidney transplantation and kidney transplantation alone in recipients with type 1 diabetes mellitus: a systematic review and meta-analysis.

Harsham Choksi, Rowan Klein Nulend, Tess Cooper, Eric Au, Henry Pleass, Natasha M Rogers

Abstract readReview
PubMed Publisher
In one paragraph

Review in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Harsham ChoksiCentre for Transplant and Renal Research, Westmead Institute for Medical Research, Westmead, NSW, Australia. harsham.choksi@gmail.com.
Rowan Klein NulendDepartment of Surgery, Westmead Hospital, Westmead, NSW, Australia.
Tess CooperCochrane Kidney & Transplant, Centre for Kidney Research, The Children's Hospital at Westmead, Westmead, NSW, Australia.
Eric AuMelbourne School of Population and Global Health, University of Melbourne, Parkville, VIC, Australia.
Henry PleassFaculty of Medicine and Health, The University of Sydney, Camperdown, NSW, Australia.
Natasha M RogersCentre for Transplant and Renal Research, Westmead Institute for Medical Research, Westmead, NSW, Australia. natasha.rogers@sydney.edu.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisSimultaneous pancreas-kidney transplantation (SPKTx) and kidney transplantation alone (KTx) are common treatment modalities for individuals with type 1 diabetes with end-stage kidney disease. This study compared metabolic and macrovascular disease outcomes between SPKTx and KTx in recipients with type 1 diabetes.

methodsWe conducted a systematic search of the Embase, MEDLINE and Scopus databases (last searched 23 February 2025). We included retrospective and case-control studies, owing to a lack of randomised controlled trials in English, with adult patients. We excluded studies reporting on a return to dialysis post transplant, islet-kidney transplantation or separate pancreas-kidney transplants. Bias and study quality were assessed via the Newcastle-Ottawa scale for cohort studies. Demographic and outcome data were synthesised as both categorical and continuous data, with pooled means and summary statistics computed where applicable. Meta-analysis was performed on post-transplant outcomes in studies evaluating total cholesterol (TC), triglyceride (TG) level, HDL, LDL, blood pressure, HbA

resultsA total of 15 studies (n=564 SPKTx, 419 KTx) were included. Meta-analysis demonstrated lower post-transplant TC (mean difference -0.41 mmol/l [95% CI -0.60, -0.22], p<0.01, I CONCLUSIONS/

interpretationSPKTx demonstrates a superior metabolic profile post transplant to that in KTx in recipients with type 1 diabetes. However, this does not translate into differences in the risk of CAD or PVD post transplant, with PVD accounting for the greatest burden of macrovascular disease. REGISTRATION: This protocol has been registered a priori on PROSPERO (CRD42024622408).

Indexed as

Cardiovascular diseaseCerebrovascular diseaseGlycaemic managementKidney transplantationLipid profileMacrovascular diseaseMeta-analysisMetabolic outcomesPeripheral vascular diseaseSimultaneous pancreas–kidney transplantationSystematic reviewType 1 diabetes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.